Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport Academy Medical Centre, shared a post on X:
“A nice review on management of oligometastatic disease in gastric/esophageal cancer.
Definition remains elusive.
Two key trials-
IKF-575/RENAISSANCE phase III trial showed no significant overall survival difference between systemic therapy alone and systemic therapy combined with local therapy for patients with gastric or gastroesophageal junc-tion cancer and de-novo OMD, except for patients with retroperitoneal lymph node metastases only
The ESO-Shanghai 13 phase II trial demonstrated superiority of adding local therapy to systemic therapy for progression-free and overall survival in oligometastatic esophageal squamous cell carcinoma.
Benefit perhaps more in ESCC?
Multi-D discussion paramount. Appropriate patient selection challenging but very important.”
Oligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It?
Authors: Tiuri E. Kroese et al.
